Figure 1. Estimated Probability Of Achieving Initial Headache Response Within 4 Hours Of Treatment In Pooled Trials 1, 2, And 3a (Sumatriptan Fig1)
Sumatriptan Tablet
Product Images NDC 68788-9547
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Sumatriptan (NDC 68788-9547). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Preferred Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Figure 2. The Estimated Probability Of Patients Taking A Second Dose Of Sumatriptan Tablets Or Other Medication To Treat Migraine Over The 24 Hours Following The Initial Dose Of Study Treatment In Pooled Trials 1, 2, And 3a (Sumatriptan Fig2)
Estimated Probability of Remedication or Rescue is displayed in percentage for different dosages of a particular medication, including placebo. The has not properly read the text for the line "Tie o Howrs From bilial Bese".*
Sumatriptan Succinate Tablets, Usp 50mg (Sumatriptan Fig4)
Sumatriptan Pharmaceutical is a generic medicine used for the treatment of migraines. It should only be taken by the person who is prescribed this medicine. Each 50mg tablet contains Sumatriptan Succinate. It is manufactured by Aurobindo Pharma in Dayton, NJ. The product number for this medicine is (D) and (NDO) for insurance purposes, with the lot number being Bart. A warning is highlighted on the packaging, but the text is not available.*
Chemical Structure (Sumatriptan Str)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
